← Back to Search
CD24: A Potential New Marker In Differentiating Malignant Mesothelioma From Pulmonary Adenocarcinoma
D. Pinato, Paul Nya, R. Sharma, F. Mauri
Published 2012 · Medicine
Download PDFAnalyze on Scholarcy
Background The differential diagnosis between malignant mesothelioma (MM) and metastatic lung adenocarcinoma (MLA) often relies on immunohistochemical studies, with no individual immunomarker holding satisfactory discrimination ability. Methods We investigated the diagnostic accuracy of CD24 immunoreactivity on 134 patients including 69 cases of MM and 65 MLA. Results The expression of CD24 favoured MLA, with 57/65 cases showing positive cytoplasmic staining compared with 9/69 MM (p<0.001), whose immunopositivity pattern was prevalently membranous (7/9 cases). Conclusions CD24 positivity can accurately discriminate MM from MLA. Prospective studies are warranted to clarify whether CD24 could integrate with other immunomarkers to facilitate the diagnosis of mesothelial malignancies.
This paper references
Novel marker D2-40, combined with calretinin, CEA, and TTF-1 : an optimal set of immunodiagnostic markers for pleural mesothelioma
三村 剛史 (2007)
CD24 induces localization of β1 integrin to lipid raft domains
S. Runz (2008)
h-Caldesmon, a Useful Positive Marker in the Diagnosis of Pleural Malignant Mesothelioma, Epithelioid Type
C. Comin (2006)
Expression of calretinin by breast carcinoma and the potential for misdiagnosis of mesothelioma
G. Powell (2011)
CD24 Expression Is a Novel Prognostic Factor in Esophageal Squamous Cell Carcinoma
A. Sano (2008)
What is the best way to diagnose and stage malignant pleural mesothelioma?
I. Zahid (2011)
Validation of a minimal panel of antibodies for the diagnosis of malignant pleural mesothelioma
S. Kao (2011)
CD24 expression causes the acquisition of multiple cellular properties associated with tumor growth and metastasis.
P. Baumann (2005)
Calretinin: a novel immunocytochemical marker for mesothelioma.
C. Doglioni (1996)
Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group.
A. Husain (2009)
Mechanisms of FUS1/TUSC2 deficiency in mesothelioma and its tumorigenic transcriptional effects
A. Ivanova (2009)
The immunohistochemical diagnostic panel for epithelial mesothelioma: a reevaluation after heat-induced epitope retrieval.
J. R. Riera (1997)
Value of the Mesothelium-Associated Antibodies Thrombomodulin, Cytokeratin 5/6, Calretinin, and CD44H in Distinguishing Epithelioid Pleural Mesothelioma from Adenocarcinoma Metastatic to the Pleura
P. Cury (2000)
Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity
H. Yaziji (2006)
The novel oncogene CD24 and its arising role in the carcinogenesis of the GI tract: from research to therapy
E. Sagiv (2008)
Regulation of E-cadherin and TGF-beta3 expression by CD24 in cultured oral epithelial cells.
P. Ye (2006)
CD24, a mucin-type glycoprotein, is a ligand for P-selectin on human tumor cells.
S. Aigner (1997)
Immunocytochemical characterization of malignant mesothelioma and carcinoma metastatic to the pleura: IOB3—A new tumor marker
C. Kortsik (2008)
CD24, a Novel Cancer Biomarker, Predicting Disease-Free Survival of Non-small Cell Lung Carcinomas: A Retrospective Study of Prognostic Factor Analysis from the Viewpoint of Forthcoming (Seventh) New TNM Classification
H. Lee (2010)
Identification of cancer stem cell markers in human malignant mesothelioma cells.
Farhana Ishrat Ghani (2011)
Inflammation-Based Prognostic Indices in Malignant Pleural Mesothelioma
D. Pinato (2012)
Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma.
C. Comin (2001)
Sarcomatoid mesothelioma and its histological mimics: a comparative immunohistochemical study
D. Lucas (2003)
Interpretation and Uses of Medical Statistics.
P. N. Lee (1969)
The CD24/P-selectin binding pathway initiates lung arrest of human A125 adenocarcinoma cells.
J. Friederichs (2000)
Immunohistochemistry and molecular diagnostics of pleural malignant mesothelioma.
P. Betta (2012)
The Immunohistochemical Diagnosis of Mesothelioma: A Comparative Study of Epithelioid Mesothelioma and Lung Adenocarcinoma
N. Ordóñez (2003)
CD24 induces localization of beta1 integrin to lipid raft domains.
S. Runz (2008)
Claudins in differential diagnosis between mesothelioma and metastatic adenocarcinoma of the pleura
Y. Soini (2006)
Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma
K. Kushitani (2007)
This paper is referenced by
Malignant pleural mesothelioma: current and future perspectives.
Konstantinos Porpodis (2013)
CD24 promotes HCC progression via triggering Notch-related EMT and modulation of tumor microenvironment
X. Wan (2015)